William R Wilcox

Fabry disease and COVID-19: international expert recommendations for management based on real-world experience

J. Oliveira, J. Politei, R. Hopkin, 2020, Clinical kidney journal.

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

R. Desnick, W. Wilcox, Philip J. Lee, 2004, American journal of human genetics.

Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.

J. Charrow, M. Irving, C. Bacino, 2023, The Lancet. Child & adolescent health.

Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice

J. Hoover-Fong, Ricki S. Carroll, E. Lausch, 2023, Advances in therapy.